Want to see AQST full AI Analyst Report?
AQST Stock Chart & Stats
$3.68
$0.06(1.77%)
At close: 4:00 PM EDT
$3.68
$0.06(1.77%)
Day’s Range― - ―
52-Week Range$2.93 - $7.55
Previous CloseN/A
Volume1.45M
Average Volume (3M)2.09M
Market Cap
$576.10M
Enterprise Value$570.57
Total Cash (Recent Filing)$98.49M
Total Debt (Recent Filing)$59.00M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 09, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding125,511,650
10 Day Avg. Volume1,852,464
30 Day Avg. Volume2,086,678
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)-23.41
Price to Sales (P/S)17.69
P/FCF Ratio-14.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.75Price Target Upside137.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$50.67M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong quarterly and year-to-date growth indicates improving demand across manufacturing, supply, licensing and royalty activities. Sustained expansion would strengthen the commercial base and provide a broader platform for future product launches.
Anaphylm Development ProgressCompleted studies directly address deficiencies cited in the FDA response and reduce key development risks. Improved usability and comparable self-administration PK could support Anaphylm’s differentiation if approval and commercialization are achieved.
Improving Operating EfficiencyThe combination of solid gross economics and materially lower adjusted EBITDA losses suggests operating leverage and better spending discipline. Continued improvement could narrow the path to breakeven as revenue scales across products and partnerships.
Bears Say
Persistent Losses And Cash BurnThe company remains deeply unprofitable and consumes substantial cash despite revenue growth and acceptable gross margins. Unless operating improvements continue, ongoing funding needs could constrain investment capacity and increase dependence on external capital.
Balance Sheet PressureNegative equity and meaningful debt reduce financial flexibility and heighten refinancing or dilution risk. This constrained capital base may limit the company’s ability to absorb setbacks, fund launches, or sustain operations while losses persist.
Approval And Launch DependenceAnaphylm’s commercial opportunity depends on FDA review, payer coverage and successful conversion from established auto-injectors. Contingent launch financing adds execution risk, while delays or weaker adoption could postpone revenue and extend cash needs.
Aquestive Therapeutics News
AQST FAQ
What was Aquestive Therapeutics, Inc.’s price range in the past 12 months?
Aquestive Therapeutics, Inc. lowest stock price was $2.93 and its highest was $7.55 in the past 12 months.
What is Aquestive Therapeutics, Inc.’s market cap?
Aquestive Therapeutics, Inc.’s market cap is $576.10M.
When is Aquestive Therapeutics, Inc.’s upcoming earnings report date?
Aquestive Therapeutics, Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 80 days.
How were Aquestive Therapeutics, Inc.’s earnings last quarter?
Aquestive Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.105 by -$0.075.
Is Aquestive Therapeutics, Inc. overvalued?
According to Wall Street analysts Aquestive Therapeutics, Inc.’s price is currently Undervalued.
Does Aquestive Therapeutics, Inc. pay dividends?
Aquestive Therapeutics, Inc. does not currently pay dividends.
What is Aquestive Therapeutics, Inc.’s EPS estimate?
Aquestive Therapeutics, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Aquestive Therapeutics, Inc. have?
Aquestive Therapeutics, Inc. has 125,511,650 shares outstanding.
What happened to Aquestive Therapeutics, Inc.’s price movement after its last earnings report?
Aquestive Therapeutics, Inc. reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.105. Following the earnings report the stock price went down -4.082%.
Which hedge fund is a major shareholder of Aquestive Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AQST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aquestive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (137.77% Upside)
$8.75 (137.77% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 67%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 775.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $311.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
40.99%
Trailing 12-Months
Company Description
Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
AQST Company Deck
AQST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial progress on the Anaphylm program (completed human factors and PK studies, strong human factors improvements, favorable PD data) and solid financial execution (significant year-over-year revenue growth, materially improved adjusted EBITDA, strong cash balance and a new $150M debt facility). The principal negatives were a large one-time debt extinguishment charge that widened reported Q2 net loss, higher Q2 SG&A from legal and severance costs, a few residual human factors issues (very small), and remaining uncertainty around FDA review timing, payer coverage and reliance on contingent launch funding. On balance, operational, clinical and liquidity positives meaningfully outweigh the near-term financial and execution risks.View all AQST earnings summariesAQST Stock 12 Month Forecast
Average Price Target
$8.75
▲(137.77% Upside)
Technical Analysis
Ownership Overview
2.25% Insiders
9.16% Mutual Funds
23.67% Other Institutional Investors
55.44% Public Companies and
Individual Investors